TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Goal Directed Therapy for Patients Undergoing Major Vascular Surgery
Brief Summary: The management and delivery of intravenous fluids during surgical operations is one of the important duties for anesthesiologists.

The goal of this study was to determine if goal directed fluid therapy, titrated using the FloTrac monitor's measurement of stroke volume variation results in a decrease in the length of stay of patients undergoing open abdominal aneurysm repair.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Procedure: Standard Care | Arm Label: 2; Type: OTHER; Interventions: Procedure: Fast Track care | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Fast Track care; Assigned to Arm(s): 2
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13% | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Fluid titrated at the discretion of the attending anesthesiologist | Intervention Type: OTHER; Name: Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Fluid titrated at the discretion of the attending anesthesiologist; Assigned to Arm(s): Control
C: Arm Label: Standard fluid management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard fluid management | Arm Label: Goal directed fluid therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Goal directed fluid therapy with the Edwards EV1000 system | Intervention Type: PROCEDURE; Name: Standard fluid management; Assigned to Arm(s): Standard fluid management | Intervention Type: DEVICE; Name: Goal directed fluid therapy with the Edwards EV1000 system; Assigned to Arm(s): Goal directed fluid therapy
D: Arm Label: Individualized Goal Directed Therapy (iGDT); Type: EXPERIMENTAL; Interventions: Procedure: Individualized Goal Directed Therapy | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Control Group | Intervention Type: PROCEDURE; Name: Individualized Goal Directed Therapy; Assigned to Arm(s): Individualized Goal Directed Therapy (iGDT) | Intervention Type: PROCEDURE; Name: Control Group; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes
Brief Summary: Project 1, Study 1 will evaluate the relationship between nicotine yield of very low nicotine content cigarettes and cigarettes smoked per day, nicotine exposure, discomfort/dysfunction, other health-related behaviors, nicotine/tobacco dependence, biomarkers of tobacco exposure, intention to quit, compensatory smoking, other tobacco use, cigarette characteristics, cognitive function, cardiovascular function, and perceived risk. We will also consider differences between conditions in compliance with product use.


Options:
A: Arm Label: 0.8 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.26 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.12 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.07 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.03 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.04 mg nicotine with 13 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: Usual brand; Type: OTHER; Interventions: Other: very low nicotine content cigarettes | Intervention Type: OTHER; Name: very low nicotine content cigarettes; Assigned to Arm(s): 0.03 mg nicotine with 9 mg tar, 0.04 mg nicotine with 13 mg tar, 0.07 mg nicotine with 9 mg tar, 0.12 mg nicotine with 9 mg tar, 0.26 mg nicotine with 9 mg tar, 0.8 mg nicotine with 9 mg tar, Usual brand
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection
Brief Summary: This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus two placebos in the adjuvant treatment of melanoma after surgical resection. Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk \[Stage IIIa (lymph node metastasis \>1 mm), IIIb or IIIc\] cutaneous melanoma were screened for eligibility. Subjects were randomized to receive either dabrafenib (150 milligram (mg) twice daily \[BID\]) and trametinib (2 mg once daily \[QD\]) combination therapy or two placebos for 12 months.


Options:
A: Arm Label: Dabrafenib plus Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vemurafenib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib plus Trametinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib plus Trametinib
B: Arm Label: Dabrafenib and trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Dabrafenib and trametinib placebos; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Dabrafenib and trametinib placebos
C: Arm Label: Arm A consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab - Arm A | Arm Label: Arm B consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab + Ipilimumab - Arm B | Intervention Type: DRUG; Name: Nivolumab - Arm A; Assigned to Arm(s): Arm A consists of 3 phases or steps | Intervention Type: DRUG; Name: Nivolumab + Ipilimumab - Arm B; Assigned to Arm(s): Arm B consists of 3 phases or steps
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: hu14.18-IL2 | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: hu14.18-IL2 | Intervention Type: DRUG; Name: hu14.18-IL2; Assigned to Arm(s): A | Intervention Type: DRUG; Name: hu14.18-IL2; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection
Brief Summary: This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus two placebos in the adjuvant treatment of melanoma after surgical resection. Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk \[Stage IIIa (lymph node metastasis \>1 mm), IIIb or IIIc\] cutaneous melanoma were screened for eligibility. Subjects were randomized to receive either dabrafenib (150 milligram (mg) twice daily \[BID\]) and trametinib (2 mg once daily \[QD\]) combination therapy or two placebos for 12 months.


Options:
A: Arm Label: Dabrafenib plus Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vemurafenib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib plus Trametinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib plus Trametinib
B: Arm Label: Dabrafenib and trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Dabrafenib and trametinib placebos; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Dabrafenib and trametinib placebos
C: Arm Label: WEX only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wide Excision | Arm Label: WEX + SLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sentinel Lymph Node Dissection | Arm Label: WEX+SLND+CLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Complete Lymph Node Dissection | Intervention Type: PROCEDURE; Name: Sentinel Lymph Node Dissection; Assigned to Arm(s): WEX + SLND | Intervention Type: PROCEDURE; Name: Complete Lymph Node Dissection; Assigned to Arm(s): WEX+SLND+CLND | Intervention Type: PROCEDURE; Name: Wide Excision; Assigned to Arm(s): WEX only
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial
Brief Summary: The purpose of this multicentric, randomized controlled trial is to assess whether the timing of renal replacement therapy initiation (early vs delayed) has an impact on mortality at 90 days in patients with severe acute kidney injury at the failure stage (according to RIFLE criteria) during the initial phase of septic shock.


Options:
A: Intervention Type: PROCEDURE; Name: renal replacement therapy (intermittent or continuous); Assigned to Arm(s): N/A
B: Arm Label: Standard RRT initiation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard RRT initiation | Arm Label: Accelerated RRT initiation; Type: EXPERIMENTAL; Interventions: Other: Accelerated RRT initiation | Intervention Type: OTHER; Name: Accelerated RRT initiation; Assigned to Arm(s): Accelerated RRT initiation | Intervention Type: OTHER; Name: Standard RRT initiation; Assigned to Arm(s): Standard RRT initiation
C: Arm Label: Early initiation of RRT; Type: EXPERIMENTAL; Interventions: Procedure: Renal Remplacement Therapy | Arm Label: Deferred RRT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal Remplacement Therapy | Intervention Type: PROCEDURE; Name: Renal Remplacement Therapy; Assigned to Arm(s): Deferred RRT, Early initiation of RRT
D: Arm Label: early group; Type: EXPERIMENTAL; Interventions: Procedure: continuous renal replacement therapies | Arm Label: delayed group; Type: EXPERIMENTAL; Interventions: Procedure: continuous renal replacement therapies | Intervention Type: PROCEDURE; Name: continuous renal replacement therapies; Assigned to Arm(s): delayed group, early group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial
Brief Summary: The purpose of this multicentric, randomized controlled trial is to assess whether the timing of renal replacement therapy initiation (early vs delayed) has an impact on mortality at 90 days in patients with severe acute kidney injury at the failure stage (according to RIFLE criteria) during the initial phase of septic shock.


Options:
A: Arm Label: Early initiation of RRT; Type: EXPERIMENTAL; Interventions: Procedure: Renal Remplacement Therapy | Arm Label: Deferred RRT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal Remplacement Therapy | Intervention Type: PROCEDURE; Name: Renal Remplacement Therapy; Assigned to Arm(s): Deferred RRT, Early initiation of RRT
B: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h
C: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
D: Arm Label: Early RRT strategy; Type: EXPERIMENTAL; Interventions: Procedure: Early RRT strategy | Arm Label: Delayed RRT strategy; Type: EXPERIMENTAL; Interventions: Procedure: Delayed RRT strategy | Intervention Type: PROCEDURE; Name: Early RRT strategy; Assigned to Arm(s): Early RRT strategy | Intervention Type: PROCEDURE; Name: Delayed RRT strategy; Assigned to Arm(s): Delayed RRT strategy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Lifestyle Intervention for Employees With Prediabetes
Brief Summary: The purpose of this study is to evaluate the impact of a worksite lifestyle intervention for diabetes prevention among employees with prediabetes.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
B: Arm Label: Low Glycemic Index Diet; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index diet | Arm Label: High Fiber Diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High Cereal Fibre Diets | Intervention Type: OTHER; Name: Low Glycemic Index diet; Assigned to Arm(s): Low Glycemic Index Diet | Intervention Type: OTHER; Name: High Cereal Fibre Diets; Assigned to Arm(s): High Fiber Diet
C: Intervention Type: BEHAVIORAL; Name: high protein & low glycemic index diets; Assigned to Arm(s): N/A
D: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling; Assigned to Arm(s): Lifestyle counseling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Lifestyle Intervention for Employees With Prediabetes
Brief Summary: The purpose of this study is to evaluate the impact of a worksite lifestyle intervention for diabetes prevention among employees with prediabetes.


Options:
A: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: Worksite Environmental Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: weight gain prevention | Arm Label: No-contact control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: weight gain prevention; Assigned to Arm(s): Worksite Environmental Intervention
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Individual counseling; Type: EXPERIMENTAL; Interventions: Behavioral: individual counseling | Arm Label: group counseling; Type: EXPERIMENTAL; Interventions: Behavioral: group counseling | Arm Label: aerobic training; Type: EXPERIMENTAL; Interventions: Behavioral: aerobic training | Intervention Type: BEHAVIORAL; Name: individual counseling; Assigned to Arm(s): Individual counseling | Intervention Type: BEHAVIORAL; Name: group counseling; Assigned to Arm(s): group counseling | Intervention Type: BEHAVIORAL; Name: aerobic training; Assigned to Arm(s): aerobic training
D: Arm Label: weight loss counseling; Type: EXPERIMENTAL; Interventions: Behavioral: weight loss counseling | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: weight loss counseling; Assigned to Arm(s): weight loss counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Lifestyle Intervention for Employees With Prediabetes
Brief Summary: The purpose of this study is to evaluate the impact of a worksite lifestyle intervention for diabetes prevention among employees with prediabetes.


Options:
A: Arm Label: multi-component intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Sit-stand workstation only; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Usual practice (seated workstation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sit-stand workstation provision; Assigned to Arm(s): Sit-stand workstation only, multi-component intervention
B: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling; Assigned to Arm(s): Lifestyle counseling
C: Arm Label: 1-800-QUIT-NOW Telephone Hotline; Type: OTHER; Interventions: Other: 1-800-QUIT-NOW Telephone Hotline | Arm Label: Tobacco Tactics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Tactics Web-Based Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco Tactics Web-Based Intervention; Assigned to Arm(s): Tobacco Tactics Intervention | Intervention Type: OTHER; Name: 1-800-QUIT-NOW Telephone Hotline; Assigned to Arm(s): 1-800-QUIT-NOW Telephone Hotline
D: Arm Label: Stair walking; Type: EXPERIMENTAL; Interventions: Behavioral: Stair walking | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stair walking | Intervention Type: BEHAVIORAL; Name: Stair walking; Assigned to Arm(s): Control, Stair walking

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Parenteral Nutrition With Different Lipid Emulsions in Preterm Infants
Brief Summary: Previous studies have suggested that olive oil-based emulsion is safe and well tolerated in preterm infants, a showed efficacy and a good clinical and biological safety profile. The objective of this study was to assess the effects of a new olive-oil based lipid emulsion compared with the traditional lipid emulsions.


Options:
A: Arm Label: SMOFlipid; Type: EXPERIMENTAL; Interventions: Other: SMOFlipid | Arm Label: Lipofundin; Type: OTHER; Interventions: Other: Lipofundin | Intervention Type: OTHER; Name: SMOFlipid; Assigned to Arm(s): SMOFlipid | Intervention Type: OTHER; Name: Lipofundin; Assigned to Arm(s): Lipofundin
B: Arm Label: Smoflipid; Type: EXPERIMENTAL; Interventions: Drug: SMOFLIPID | Arm Label: Intralipid; Type: ACTIVE_COMPARATOR; Interventions: Drug: INTRALIPID | Intervention Type: DRUG; Name: SMOFLIPID; Assigned to Arm(s): Smoflipid | Intervention Type: DRUG; Name: INTRALIPID; Assigned to Arm(s): Intralipid
C: Arm Label: Olive oil lipid emulsion; Type: EXPERIMENTAL; Interventions: Drug: ClinOleic | Arm Label: MCT/LCT lipid emulsion; Type: EXPERIMENTAL; Interventions: Drug: Lipofundin | Arm Label: LCT lipid emulsion; Type: EXPERIMENTAL; Interventions: Drug: Intralipid | Intervention Type: DRUG; Name: ClinOleic; Assigned to Arm(s): Olive oil lipid emulsion | Intervention Type: DRUG; Name: Lipofundin; Assigned to Arm(s): MCT/LCT lipid emulsion | Intervention Type: DRUG; Name: Intralipid; Assigned to Arm(s): LCT lipid emulsion
D: Arm Label: 1) Intralipid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intralipid 20% | Arm Label: 2) SMOFlipid; Type: EXPERIMENTAL; Interventions: Drug: SMOFlipid 20% | Intervention Type: DRUG; Name: Intralipid 20%; Assigned to Arm(s): 1) Intralipid | Intervention Type: DRUG; Name: SMOFlipid 20%; Assigned to Arm(s): 2) SMOFlipid

Answer: C